Illustration: Gabriella Turrisi/Axios
Biofourmis raised $300 million in a Series D round led by General Atlantic with participation from CVS Health and others at a valuation of nearly $1.3 billion.
Why it matters: The Boston-based maker of remote home care tools is among a slate of companies raking in pandemic-era funding for tools to help patients manage their health at home.
